Shots: Several undulating factors coalesce to inadvertently shape the biopharma industry Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list. Jesse Mendelsohn, SVP at Model N, emphasizes the…